|By PR Newswire||
|April 11, 2014 08:01 AM EDT||
NEW YORK, April 11, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ), Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA), and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Regeneron Pharmaceuticals, Inc. Analyst Notes
On April 1, 2014, Regeneron Pharmaceuticals, Inc. (Regeneron), together with Sanofi, announced that the Phase 2 study with alirocumab, an antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9) yielded positive results after it demonstrated a bad cholesterol percentage reduction in patients randomized to receive one of three doses of the said antibody every other week combined with statin therapy, as compared with patients receiving placebo. According to the Company, in week 12, the mean percentage reduction in lipoprotein-cholesterol (LDL-C) receiving alirocumab in 50mg, 75mg, and 150mg doses every other week was 55%, 62%, and 72%, respectively, compared with 3% mean reduction rate in the placebo group. Commenting on the results, George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer and Laboratories President, Regeneron, said, "Hypercholesterolemia is a growing problem in Japan and many patients are poorly-controlled on statins. The results from this trial support the efficacy and safety of alirocumab at a range of doses in Japanese patients." The full analyst notes on Regeneron Pharmaceuticals, Inc. will be available to download free of charge at:
Questcor Pharmaceuticals, Inc. Analyst Notes
On March 20, 2014, Questcor Pharmaceuticals, Inc. (Questcor) announced that it is contributing $175,000 to Child Neurology Society (CNS) and Child Neurology Foundation (CNF) to fund the Philip R. Dodge Young Investigator Award, totalling the Company's commitment to the Dodge award to $250,000. Steve Cartt, CEO, Questcor, said, "Questcor's support of the child neurology community is unwavering and we are very pleased to support the Philip R. Dodge Young Investigator Award. Supporting this cornerstone program of the Child Neurology Society will help encourage young scientists to focus their research efforts on initiatives to advance the understanding and treatment of pediatric neurological disorders. Our hope is that these efforts will help pave the way for new and more effective treatments for the many children impacted by these disorders." The full analyst notes on Questcor Pharmaceuticals, Inc. are available to download free of charge at:
Jazz Pharmaceuticals plc Analyst Notes
On March 31, 2014, Jazz Pharmaceuticals plc (Jazz), together with Gentium S.p.A., announced the European commercial launching of Defitelio (defibrotide), the first licensed product designed to treat sever hepatic veno-occlusive disease (severe VOD) in patients over one month of age undergoing haematopoietic stem cell transplantation (HSCT) therapy. According to the Company, severe VOD is a complex and unpredictable disease affecting in over 80% of European patients. Jazz stated that the efficacy of Defitelio to treat sVOD in HSCT patients resulted from a successful phase 3 trial that provided a significant increase of 52% survival rates among patients treated for 100 days compared with patients in the historical control group. The Company informed that Defitelio will be launched in 27 additional European countries starting in 2014 until next year. The full analyst notes on Jazz Pharmaceuticals plc are available to download free of charge at:
Ariad Pharmaceuticals, Inc. Analyst Notes
On March 24, 2014, Ariad Pharmaceuticals, Inc. (Ariad) announced the initiation of the pivotal Phase 2 trial of AP26113 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) previously treated with crizotinib. Ariad informed that ALK in Lung Cancer Trial of AP26113 (ALTA) is designed to determine the safety and efficacy of AP26113 in patients who tested positive for anaplastic lymphoma kinase (ALK+) oncogene. According to the Company, the ALTA trial's primary goal is to achieve an objective response rate (ORR) measured by RECIST criteria, while recording time to response, duration of response, disease control rate, progression-free survival, overall survival, safety and tolerability comes secondary. Ariad added that full patient enrolment is expected in Q3 2015 and the Company expects to report first data from the trial in during the medical meeting in 2015. The full analyst notes on Ariad Pharmaceuticals, Inc. are available to download free of charge at:
BioMarin Pharmaceutical Inc. Analyst Notes
On March 21, 2014, BioMarin Pharmaceutical Inc. (BioMarin) announced the appointment of Dennis J. Slamon, M.D. Ph.D., Clinical/Translational Research Director Revlon /UCLA Women's Cancer Research Program Director, to the Company's Board of Directors. According to the Company, Dr. Slamon won nearly two dozen national and international research awards honoring his scientific endeavors, and has mostly changed the way cancer is treated. Commenting on the appointment, Jean-Jacques Bienaimé, CEO, BioMarin, said, "I am delighted that Dr. Slamon will be joining BioMarin's board. His experience in translating discovery into medicines is aligned with our mission to treat patients with unmet medical needs based on a specific knowledge of the molecular basis of their disease. As BioMarin builds its pipeline of early and late stage therapies, Dr. Slamon's support will help us achieve success in the clinic." The full analyst notes on BioMarin Pharmaceutical Inc. are available to download free of charge at:
About Analysts Review
We provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] AnalystsReview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the Procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
More and more brands have jumped on the IoT bandwagon. We have an excess of wearables – activity trackers, smartwatches, smart glasses and sneakers, and more that track seemingly endless datapoints. However, most consumers have no idea what “IoT” means. Creating more wearables that track data shouldn't be the aim of brands; delivering meaningful, tangible relevance to their users should be. We're in a period in which the IoT pendulum is still swinging. Initially, it swung toward "smart for smar...
Oct. 23, 2016 05:30 PM EDT Reads: 817
Kubernetes, Docker and containers are changing the world, and how companies are deploying their software and running their infrastructure. With the shift in how applications are built and deployed, new challenges must be solved. In his session at @DevOpsSummit at19th Cloud Expo, Sebastian Scheele, co-founder of Loodse, will discuss the implications of containerized applications/infrastructures and their impact on the enterprise. In a real world example based on Kubernetes, he will show how to ...
Oct. 23, 2016 05:30 PM EDT Reads: 2,844
SYS-CON Events announced today that SoftNet Solutions will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. SoftNet Solutions specializes in Enterprise Solutions for Hadoop and Big Data. It offers customers the most open, robust, and value-conscious portfolio of solutions, services, and tools for the shortest route to success with Big Data. The unique differentiator is the ability to architect and ...
Oct. 23, 2016 05:00 PM EDT Reads: 735
Successful digital transformation requires new organizational competencies and capabilities. Research tells us that the biggest impediment to successful transformation is human; consequently, the biggest enabler is a properly skilled and empowered workforce. In the digital age, new individual and collective competencies are required. In his session at 19th Cloud Expo, Bob Newhouse, CEO and founder of Agilitiv, will draw together recent research and lessons learned from emerging and established ...
Oct. 23, 2016 05:00 PM EDT Reads: 1,228
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Eric Robertson, General Manager at CollabNet, will discuss how customers are able to achieve a level of transparency that e...
Oct. 23, 2016 05:00 PM EDT Reads: 832
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
Oct. 23, 2016 04:45 PM EDT Reads: 2,400
“Media Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. CloudBerry Backup is a leading cross-platform cloud backup and disaster recovery solution integrated with major public cloud services, such as Amazon Web Services, Microsoft Azure and Google Cloud Platform.
Oct. 23, 2016 04:30 PM EDT Reads: 1,317
SYS-CON Events announced today that Embotics, the cloud automation company, will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Embotics is the cloud automation company for IT organizations and service providers that need to improve provisioning or enable self-service capabilities. With a relentless focus on delivering a premier user experience and unmatched customer support, Embotics is the fas...
Oct. 23, 2016 04:30 PM EDT Reads: 799
In the next five to ten years, millions, if not billions of things will become smarter. This smartness goes beyond connected things in our homes like the fridge, thermostat and fancy lighting, and into heavily regulated industries including aerospace, pharmaceutical/medical devices and energy. “Smartness” will embed itself within individual products that are part of our daily lives. We will engage with smart products - learning from them, informing them, and communicating with them. Smart produc...
Oct. 23, 2016 04:15 PM EDT Reads: 1,473
As ridesharing competitors and enhanced services increase, notable changes are occurring in the transportation model. Despite the cost-effective means and flexibility of ridesharing, both drivers and users will need to be aware of the connected environment and how it will impact the ridesharing experience. In his session at @ThingsExpo, Timothy Evavold, Executive Director Automotive at Covisint, will discuss key challenges and solutions to powering a ride sharing and/or multimodal model in the a...
Oct. 23, 2016 03:30 PM EDT Reads: 1,473
SYS-CON Events announced today that Coalfire will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Coalfire is the trusted leader in cybersecurity risk management and compliance services. Coalfire integrates advisory and technical assessments and recommendations to the corporate directors, executives, boards, and IT organizations for global brands and organizations in the technology, cloud, health...
Oct. 23, 2016 03:30 PM EDT Reads: 1,521
In his session at 19th Cloud Expo, Claude Remillard, Principal Program Manager in Developer Division at Microsoft, will contrast how his team used config as code and immutable patterns for continuous delivery of microservices and apps to the cloud. He will show the immutable patterns helps developers do away with most of the complexity of config as code-enabling scenarios such as rollback, zero downtime upgrades with far greater simplicity. He will also have live demos of building immutable pipe...
Oct. 23, 2016 03:15 PM EDT Reads: 1,534
Rapid innovation, changing business landscapes, and new IT demands force businesses to make changes quickly. In the eyes of many, containers are at the brink of becoming a pervasive technology in enterprise IT to accelerate application delivery. In this presentation, you'll learn about the: The transformation of IT to a DevOps, microservices, and container-based architecture What are containers and how DevOps practices can operate in a container-based environment A demonstration of how Docke...
Oct. 23, 2016 03:15 PM EDT Reads: 1,582
A completely new computing platform is on the horizon. They’re called Microservers by some, ARM Servers by others, and sometimes even ARM-based Servers. No matter what you call them, Microservers will have a huge impact on the data center and on server computing in general. Although few people are familiar with Microservers today, their impact will be felt very soon. This is a new category of computing platform that is available today and is predicted to have triple-digit growth rates for some ...
Oct. 23, 2016 03:00 PM EDT Reads: 34,035
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
Oct. 23, 2016 02:30 PM EDT Reads: 1,370